Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Trial Parameters
Brief Summary
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Eligibility Criteria
Inclusion Criteria: * Patients with decompensated liver cirrhosis * 18 years or older. * Healthy individuals 18 years or older will serve as controls. Exclusion Criteria: * • Extrahepatic malignancy or recurrence of such within the last year. * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion. * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies * Previous liver transplantation. * Transfusions the last 7 days. * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.